References
- Anderson-Cook AM, Nelson L. Prices for and spending on specialty drugs in medicare part D and Medicaid: an in-depth analysis: Congressional Budget Office. 2019. [cited 2020 Apr 30]. Available from: https://www.cbo.gov/system/files?file=2019-03/55011-Specialty_Drugs_WP.pdf.
- Cubanski JR, Young K, Damico A. How does prescription drug spending and use compare across large employer plans, Medicare Part D, and Medicaid? Kaiser Family Foundation. 2019;. [cited 2020 Mar 7]. Available from: https://www.kff.org/medicare/issue-brief/how-does-prescription-drug-spending-and-use-compare-across-large-employer-plans-medicare-part-d-and-medicaid/.
- Part D Drug Spending Dashboard Methodology Centers for Medicare & Medicaid Services; 2019. [cited 2020 Mar 5]. Available from: https://www.cms.gov/files/document/medicare-part-d-drug-spending-methodology-2018.pdf.
- Medicaid Drug Spending Dashboard Methodology: Centers for Medicare & Medicaid Services; 2019. [cited 2020 Mar 5]. Available from: https://www.cms.gov/files/document/medicaid-drug-spending-methodology-2018.pdf.
- Consumer Price Index Historical Tables for U.S. City Average: U.S. Bureau of Labor Statistics. [cited 2020 Mar 8]. Available from: https://www.bls.gov/regions/mid-atlantic/data/consumerpriceindexhistorical_us_table.htm.
- McCormick N, Wallace ZS, Sacks CA, et al. Decomposition analysis of spending and price trends for biologic antirheumatic drugs in Medicare and Medicaid. Arthritis Rheumatol. 2020;72(2):234–241.